Skip to content

Post-refractive IOL Outcomes With Clareon TruPlus

Post-refractive IOL Outcomes With Clareon TruPlus

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07610226
Enrollment
35
Registered
2026-05-27
Start date
2026-06-25
Completion date
2027-06-23
Last updated
2026-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract

Brief summary

This is a prospective, single-arm, single-center, single-surgeon study evaluating the Clareon TruPlus IOL in post-refractive cataract patients. Subjects will be assessed up to 3 months post-operatively. Clinical evaluations will include refractive outcomes, visual acuity, and administration of the PRISQ Questionnaire.

Interventions

Clareon TruPlus

Sponsors

Laser Defined Vision
Lead SponsorOTHER
Sengi
CollaboratorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Willing and able to understand and sign informed consent. * Adult patients (\>45 years old) undergoing age-related cataract surgery that previously had myopic corneal refractive surgery. * Dominant eye targeted for emmetropia, non-dominant eye may be targeted for ≤-0.75D (mini-monovision). * Best monocular corrected distance visual acuity expected to be 0.1 logMAR (Snellen 20/25) or better in both eyes pre-operatively as determined by surgeon. * Normal ocular findings aside from cataract.

Exclusion criteria

* Moderate-severe corneal pathology, irregular astigmatism, preexisting macular disease and other retinal degenerative diseases, diabetic retinopathy that is expected to cause future vision loss, glaucoma, severe dry eye disease, nystagmus, strabismus, zonular laxity or dehiscence, pseudoexfoliation. * Previous history of any ocular surgery, except for myopic LASIK or PRK. * Previous hyperopic refractive surgery. * Corneal HOA ≥1.0 µm (RMS) with OPD at 4mm scan. * Any active ocular infection or inflammation.

Design outcomes

Primary

MeasureTime frameDescription
Binocular photopic BCDVA (4m)3 months postoperativelyMeasured using standard ETDRS charts and recorded in logMAR

Secondary

MeasureTime frameDescription
Binocular photopic DCIVA (66cm)3 months postoperativelyMeasured using standard ETDRS charts and recorded in logMAR
Binocular photopic UDVA (4m), UIVA (66cm)3 months postoperativelyMeasured using standard ETDRS charts and recorded in logMAR
Monocular photopic BCDVA (4m), DCIVA (66cm) in dominant and non-dominant eye3 months postoperativelyMeasured using standard ETDRS charts and recorded in logMAR
Binocular distance corrected defocus curve (+1.00 to -2.00 in 0.50D, +0.50 to -0.50 in 0.25D)3 months postoperativelyMeasured using standard ETDRS charts and recorded in logMAR
Refractive outcomes3 months postoperativelysphere, cylinder, MRSE

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORKarl Stonecipher, MD

Physicians Protocol

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 24, 2026